Pacira Biosciences Inc (NASDAQ:PCRX) VP Lauren Bullaro Riker sold 967 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $42.91, for a total value of $41,493.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Lauren Bullaro Riker also recently made the following trade(s):
- On Monday, June 10th, Lauren Bullaro Riker sold 2,126 shares of Pacira Biosciences stock. The stock was sold at an average price of $44.28, for a total value of $94,139.28.
PCRX stock opened at $43.49 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 8.62 and a quick ratio of 7.83. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 87.88, a PEG ratio of 2.47 and a beta of 1.24. Pacira Biosciences Inc has a 1-year low of $30.95 and a 1-year high of $55.00. The business’s 50 day simple moving average is $44.00.
A number of equities research analysts have recently issued reports on the company. Cowen reiterated a “hold” rating on shares of Pacira Biosciences in a research note on Friday, March 1st. Wedbush set a $85.00 price objective on Pacira Biosciences and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus reiterated a “sell” rating and set a $33.00 price objective on shares of Pacira Biosciences in a research note on Friday, March 8th. Mizuho upgraded Pacira Biosciences from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $29.00 to $38.00 in a research note on Monday, May 6th. Finally, BMO Capital Markets set a $44.00 price objective on Pacira Biosciences and gave the stock a “hold” rating in a research note on Friday, March 1st. One analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $54.53.
Hedge funds have recently bought and sold shares of the stock. Amundi Pioneer Asset Management Inc. bought a new position in Pacira Biosciences in the first quarter valued at about $65,000. Marshall Wace North America L.P. bought a new position in Pacira Biosciences in the first quarter valued at about $3,221,000. Dynamic Technology Lab Private Ltd bought a new position in Pacira Biosciences in the first quarter valued at about $1,119,000. AlphaCrest Capital Management LLC raised its position in Pacira Biosciences by 94.8% in the first quarter. AlphaCrest Capital Management LLC now owns 17,340 shares of the company’s stock valued at $660,000 after purchasing an additional 8,440 shares during the last quarter. Finally, Elk Creek Partners LLC raised its position in Pacira Biosciences by 5.3% in the first quarter. Elk Creek Partners LLC now owns 564,576 shares of the company’s stock valued at $21,488,000 after purchasing an additional 28,382 shares during the last quarter. 99.13% of the stock is currently owned by institutional investors and hedge funds.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
See Also: Quiet Period
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.